ICG-ER: a new probe for photoimaging and photothermal therapy for breast cancer.

Breast cancer is common cancer type with high mortality. There are still inperfections in the traditional diagnosis and treatment methods for cancer. Photoacoustic imaging combines the advantages of high specificity and deep tissue penetration and is especially suitable for early cancer detection and treatment monitoring. With its specificity and noninvasiveness; photothermal therapy has become one of the best representative treatment methods. Indocyanine green (ICG) is a near-infrared imaging reagent approved by the FDA for clinical application, with a potential application for photothermal therapy. ICG has low targeting specificity. Through the combination of EB and ICG, the timeliness of ICG circulation in vivo is improved, and the tumor targeting of ICG-E is improved by using RGD. ICG-ER, an integrated optical probe for diagnosis and treatment, was constructed, and high uptake of ICG-ER by 4T1 cells was observed by flow cytometry and confocal laser scanning microscopy (CLSM). ICG-ER photoacoustic signal intensity is concentration-dependent. In vivo photoacoustic imaging showed that the ICG-ER concentration time in the tumor site was long and reached a peak at 42 hours. Under laser irradiation, the temperature of the tumor site in mice that were injected with ICG-ER reached 56°C. After photothermal treatment, the tumor tissue in the mice showed obvious necrosis and no tumor recurrence, proving that ICG-ER has a good photothermal effect. Based on the above results, ICG-ER can be used in breast cancer optical imaging and photothermal therapy, which is expected to provide new ideas for breast cancer clinical diagnosis and treatment. AJTR